Tech pioneers keen on Hong Kong IPOs thanks to revamped listing rules

**Hong Kong has reclaimed its position as the world’s top IPO destination, driven by a surge in tech listings under revamped rules.** Total IPO proceeds on HKEX reached HK$280 billion in 2025, overtaking the New York Stock Exchange and Indian bourses for the first time in four years. The exchange’s Chapter 18C pathway, launched in March 2023 for specialist technology companies, has been a key catalyst, enabling the world’s first public listings of large language model firms like MiniMax and Zhipu AI in January 2026.</p><p class="summary-lead">**The AI boom has accelerated this momentum, with six Chapter 18C listings in Q1 2026 alone—more than in all of 2025.** Hong Kong’s IPOs accounted for over a third of global fundraising in that quarter, with nearly a fifth filed under Chapter 18C. Cornerstone investor participation has diversified significantly, reaching 85% by mid-2026, as capital flows toward markets with political stability and confidence in Chinese hard assets.</p><p class="summary-lead">**Companies like Yunji Technology illustrate how Chapter 18C enables R&D-intensive firms to scale globally.** The Beijing-based AI robotics firm, which listed in Hong Kong, designated 60% of IPO proceeds for R&D and 30% for commercialization. Listing allowed Yunji to build capital cooperation channels, validate products in Hong Kong’s international market, and expand into overseas markets with better cost efficiency.</p><p class="summary-lead">**New confidential filing channels, such as the Technology Enterprises Channel (TECH), have further streamlined the listing process for tech firms.** TECH allows earlier engagement with HKEX, helping companies address regulatory issues and reduce risks from exposing sensitive R&D information. This has positioned Hong Kong to capture the current wave of AI-driven listings, with 14 of 15 Chapter 18C issuers coming from such companies as of April 2026.</p><p class="summary-lead">**The market is seeing a clear sector concentration in industrials and technology, with 74% of 2026 proceeds from these sectors.** Biotech listings under Chapter 18A also remain strong, and HKEX is easing rules to retain commercially mature biotech firms. For AI companies requiring long-term R&D investment, Hong Kong’s financial cooperation has enhanced the feasibility of scaling and application expansion.</p><p class="summary-lead">**What to watch next:** Monitor the pace of Chapter 18C filings and the performance of newly listed AI firms, as well as any further easing of biotech listing rules that could attract more life sciences companies to Hong Kong.